Glycan bioengineering in immunogen design for tumor T antigen immunotargeting
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Glycan bioengineering in immunogen design for tumor T antigen immunotargeting. / Sendra, Victor G; Zlocowski, Natacha; Ditamo, Yanina; Copioli, Silvina; Tarp, Mads P; Bennett, Eric P; Clausen, Henrik; Roth, German A; Nores, Gustavo A; Irazoqui, Fernando J.
I: Molecular Immunology, Bind 46, Nr. 16, 2009, s. 3445-53.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glycan bioengineering in immunogen design for tumor T antigen immunotargeting
AU - Sendra, Victor G
AU - Zlocowski, Natacha
AU - Ditamo, Yanina
AU - Copioli, Silvina
AU - Tarp, Mads P
AU - Bennett, Eric P
AU - Clausen, Henrik
AU - Roth, German A
AU - Nores, Gustavo A
AU - Irazoqui, Fernando J
N1 - Keywords: Animals; Antibodies, Neoplasm; Antigens, Neoplasm; Carbohydrate Conformation; Cell Line, Tumor; Disaccharides; Epitopes, T-Lymphocyte; Female; Humans; Immunotherapy; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Vaccines, Synthetic; Xenograft Model Antitumor Assays
PY - 2009
Y1 - 2009
N2 - Bioengineering of Galbeta3GalNAcalpha, known as Thomsen-Friedenreich disaccharide (TFD), is studied to promote glycan immunogenicity and immunotargeting to tumor T antigen (Galbeta3GalNAcalpha-O-Ser/Thr). Theoretical studies on disaccharide conformations by energy minimization of structures using MM2 energy function showed that pentalysine (Lys5) linker and benzyl (Bzl) residue enhance TFD rigidity of the glycosidic bond. Antibodies raised against BzlalphaTFD-Lys5 immunogen recognize tumor T antigen. Competitive assays confirm that TFD-related structures are the main glycan epitope. Antibodies produced by glycan bioengineering recognize HT29, T47D, MCF7, and CT26 epithelial tumor cells. Epithelial tumor cell adhesion to T antigen-binding lectins and endothelial cells was lower in the presence of antibodies raised against the engineered immunogen. The immune response directed to the bioengineered glycoconjugate inhibited CT26 tumor cell proliferation and reduced tumor growth in an in vivo mouse model. These results show that TFD bioengineering is a useful immunogenic strategy with potential application in cancer therapy. The same approach can be extended to other glycan immunogens for immunotargeting purposes.
AB - Bioengineering of Galbeta3GalNAcalpha, known as Thomsen-Friedenreich disaccharide (TFD), is studied to promote glycan immunogenicity and immunotargeting to tumor T antigen (Galbeta3GalNAcalpha-O-Ser/Thr). Theoretical studies on disaccharide conformations by energy minimization of structures using MM2 energy function showed that pentalysine (Lys5) linker and benzyl (Bzl) residue enhance TFD rigidity of the glycosidic bond. Antibodies raised against BzlalphaTFD-Lys5 immunogen recognize tumor T antigen. Competitive assays confirm that TFD-related structures are the main glycan epitope. Antibodies produced by glycan bioengineering recognize HT29, T47D, MCF7, and CT26 epithelial tumor cells. Epithelial tumor cell adhesion to T antigen-binding lectins and endothelial cells was lower in the presence of antibodies raised against the engineered immunogen. The immune response directed to the bioengineered glycoconjugate inhibited CT26 tumor cell proliferation and reduced tumor growth in an in vivo mouse model. These results show that TFD bioengineering is a useful immunogenic strategy with potential application in cancer therapy. The same approach can be extended to other glycan immunogens for immunotargeting purposes.
U2 - 10.1016/j.molimm.2009.08.007
DO - 10.1016/j.molimm.2009.08.007
M3 - Journal article
C2 - 19726087
VL - 46
SP - 3445
EP - 3453
JO - Molecular Immunology
JF - Molecular Immunology
SN - 0161-5890
IS - 16
ER -
ID: 17654426